Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database

BackgroundAssociated with enzyme deficiencies causing glycosaminoglycans (GAGs) accumulation, mucopolysaccharidosis type VI (MPS VI) is lysosomal storage disorder. In the treatment of MPS VI, galsulfase (Naglazyme) is commonly used as an enzyme replacement therapy (ERT). There remains a need for com...

Full description

Saved in:
Bibliographic Details
Main Authors: Shangze Li (Author), Runcheng Huang (Author), Yuanyuan Meng (Author), Yijia Liu (Author), Jiao Qian (Author), Junjie Zou (Author), Jun Yang (Author)
Format: Book
Published: Frontiers Media S.A., 2024-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available